BPC-157 + TB-500 Blend

The BPC-157 TB-500 Blend is a pre-formulated research peptide combining two distinct tissue-repair compounds at a fixed 1:1 mass ratio. Each 20mg vial contains 10mg of BPC-157 (Body Protection Compound-157) and 10mg of TB-500, co-lyophilized as a single powder cake for reconstitution with bacteriostatic water. In the research peptide community, this combination is colloquially known as the “Wolverine Stack”, a reference to its association with accelerated connective tissue recovery in preclinical models.

BPC-157 is a 15-amino-acid synthetic peptide corresponding to a partial sequence of a protein isolated from human gastric juice. It has accumulated over 200 preclinical publications examining its effects on tendon healing, ligament repair, muscle recovery, gastrointestinal protection, and vascular formation. ⁽¹⁾ On this page, BPC-157’s role is framed specifically through the lens of musculoskeletal repair, the angiogenic and nitric oxide-driven mechanisms by which it supports blood vessel formation at injury sites. For a full overview of BPC-157’s broader mechanism, receptor interactions, and gastric protection data, see the BPC-157.

TB-500 is a 43-amino-acid synthetic peptide corresponding to the active region of thymosin beta-4, an endogenous protein involved in cell motility, migration, and tissue repair. Its primary mechanism centers on actin monomer sequestration and polymerization, which drive cytoskeletal reorganization (also referred to as reorganization) that allows repair cells to migrate into damaged tissue physically. ⁽²⁾ On this page, TB-500’s role is framed through the lens of tendon and ligament recovery, the structural repair of collagenous connective tissues, where cell migration is the rate-limiting step. For full mechanism coverage, see the TB-500.

The blend format delivers both peptides from a single verified preparation, eliminating the need to source, reconstitute, and manually combine two separate vials. The 1:1 ratio (10mg:10mg) is analytically confirmed on every production batch.

Musculoskeletal injuries, whether to tendons, ligaments, muscle, or bone, require two things to heal: a blood supply to deliver oxygen and nutrients to the injury site, and mobile repair cells that can physically reach the damaged tissue, proliferate, and lay down new extracellular matrix. BPC-157 and TB-500 each address one of these requirements through distinct molecular pathways, which is why their combined use has generated sustained research interest.

BPC-157: Vascular Supply at the Injury Site

BPC-157 stimulates angiogenesis, the formation of new blood vessels from existing vasculature, through upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and modulation of the nitric oxide (NO) system. ^(1,3) In preclinical tendon and ligament injury models, BPC-157 administration has been associated with increased vascular density at the repair site, accelerated granulation tissue formation, and improved collagen fiber organization (also spelled organization) during the remodeling (also spelled remodeling) phase of healing. ⁽¹⁾ The blood supply is the bottleneck in connective tissue repair: tendons and ligaments are naturally hypovascular (low blood supply), which is why they heal slowly compared to muscle or skin. By directly targeting angiogenesis at the injury site, BPC-157 addresses this structural limitation.

TB-500: Cellular Migration into Damaged Tissue

TB-500 acts on the intracellular actin cytoskeleton. Thymosin beta-4, the parent protein, sequesters G-actin monomers and promotes their polymerization into F-actin filaments, the structural framework that cells use to move. ^(2,4) When tissue is damaged, the repair process depends on fibroblasts, endothelial progenitor cells, and inflammatory cells physically migrating from surrounding healthy tissue into the wound site. TB-500 accelerates this migration by providing the cytoskeletal machinery these cells need to crawl through the extracellular matrix. In preclinical models, TB-500 has been associated with accelerated wound closure, improved tendon breaking strength, and enhanced cardiac tissue repair after ischaemic injury. ^(2,4)

The Convergence: Blood Supply Meets Cell Migration

The rationale for the BPC-157 TB-500 combination is that these two mechanisms are complementary, not redundant. BPC-157 builds the vascular supply that allows repair cells to reach the injury site, while TB-500 gives those cells the motility to actually infiltrate the damaged tissue once they arrive. In tendons and ligaments, where both vascular access and cell migration are rate-limiting factors, addressing both simultaneously has driven the combination’s popularity in connective tissue repair research. Neither peptide replaces the other; each removes a different bottleneck in the same healing cascade.

Preclinical research into BPC-157 and TB-500, both individually and in combination, spans a broad range of tissue-repair and recovery models. The following areas represent the primary research applications where the combination has generated the most data.

Tendon and Ligament Repair

Tendons and ligaments are dense collagenous connective tissues with limited intrinsic healing capacity due to their low vascularity and slow cell turnover. BPC-157 has been shown to accelerate Achilles tendon healing in rat transection models, with treated animals demonstrating higher breaking strength and more organized (also spelled organized) collagen fiber alignment compared to controls. ^(1,3) TB-500 has demonstrated similar benefits in equine tendon injury models, where it improved structural repair markers and reduced recovery timelines. ⁽⁴⁾ The combination targets both halves of the healing bottleneck: vascular supply (BPC-157) and cell mobilization (TB-500).

Muscle Injury Recovery

Skeletal muscle damage from crush injury, laceration, or exercise-induced microtrauma requires satellite cell activation, myoblast proliferation, and new myofibre formation. BPC-157 promotes angiogenesis within the muscle bed, ensuring adequate oxygen delivery during the energy-intensive repair process. ⁽¹⁾ TB-500 supports the migration of satellite cells and fibroblasts into the damaged zone through its actin-mediated motility effects. ⁽²⁾ Preclinical muscle injury models have examined both peptides individually, and the overlapping tissue-repair outcomes provide the mechanistic basis for their combined use in muscle recovery protocols.

Gut Barrier Integrity

While this page focuses on musculoskeletal repair, BPC-157 also has extensive preclinical evidence supporting its protective effects on the gastrointestinal tract. Murine models of NSAID-induced gastric ulceration, inflammatory bowel disease, and intestinal anastomosis healing have all shown accelerated repair with BPC-157 administration. ^(1,5) Researchers studying gut barrier function alongside musculoskeletal injury, for example, in models examining NSAID use during recovery from connective tissue damage, may find the BPC-157 TB-500 combination addresses both the primary injury and the secondary gastrointestinal insult.

Anti-Inflammatory Convergence

Both peptides demonstrate anti-inflammatory properties through different pathways. BPC-157 modulates nitric oxide synthase activity and interacts with the dopaminergic system to reduce inflammatory signaling (also known as signaling). ^(1,5) TB-500 reduces pro-inflammatory cytokine expression and promotes the shift from M1 (pro-inflammatory) to M2 (pro-repair) macrophage polarization at wound sites. ^(2,4) This convergent anti-inflammatory action helps create a tissue environment that favors repair over chronic inflammation.

No regulatory body has established dosing guidelines for the BPC-157 TB-500 combination. All dosage information in the research literature derives from individual-component preclinical studies and community-reported protocols.

BPC-157 dosing in published preclinical studies typically ranges from 10 to 50 mcg/kg in rodent models, administered intraperitoneally or subcutaneously, with dose-dependent improvements in tendon and gastric healing endpoints. ^(1,3) TB-500 preclinical protocols commonly use doses of 6 to 20 mg per administration in equine models, though rodent studies use scaled-down equivalents. ⁽⁴⁾ These figures provide reference points but cannot be directly extrapolated to combination protocols.

The Healius BPC-157 TB-500 Blend is supplied as a 20mg vial containing 10mg BPC-157 and 10mg TB-500. Adding 2.0 mL of bacteriostatic water yields a final blend concentration of 10 mg/mL (5 mg/mL of each component). At this concentration, a 0.10 mL injection (10 units on a standard U-100 insulin syringe) delivers a total of 1,000 mcg, consisting of 500 mcg BPC-157 and 500 mcg TB-500. Researchers can adjust reconstitution volume to achieve different per-unit concentrations.

Both BPC-157 and TB-500 have relatively short biological activity windows, supporting once- or twice-daily administration in most research protocols. Some protocols recommend subcutaneous injection near the area of interest (for example, peritendinous injection for tendon repair models), though systemic subcutaneous administration has also demonstrated efficacy in animal model data. ^(1,2)

For precise dose calculations, use the BPC-157 TB-500 Blend Dosage Calculator. Healius Bacteriostatic Water is available in matched volumes for reconstitution.

Neither BPC-157 nor TB-500 has received FDA approval for therapeutic use. Safety data is drawn from individual-component preclinical literature and community-reported observations.

BPC-157 has been administered in hundreds of preclinical studies at varying doses and routes, with a consistently favorable tolerability profile. No organ toxicity, mutagenicity, or significant adverse effects have been reported in the published animal literature. ^(1,5) Self-reported effects in community use include occasional injection-site discomfort, mild nausea (typically with higher doses), and transient lightheadedness.

TB-500 has been studied most extensively in equine veterinary medicine, where it has been used in performance horse recovery protocols. Published equine data reports no significant adverse effects at standard doses. ⁽⁴⁾ As with BPC-157, community-reported side effects are generally mild: injection-site irritation, transient headache, and occasional lethargy.

Regulatory Status

Both BPC-157 and TB-500 are on the FDA’s Category 2 list of bulk drug substances (added September 2023), which affects their availability through compounding pharmacies but does not restrict their sale as research peptides. ⁽⁶⁾ Both are prohibited by the World Anti-Doping Agency (WADA): BPC-157 is explicitly named under S0 (Non-Approved Substances), and TB-500 is listed under S2.2 as “Thymosin-Beta4 and its derivatives, e.g., TB-500.” ⁽⁷⁾ The blend as a whole should be treated as WADA-prohibited.

Researchers should note that both compounds are investigational and have not completed human clinical trials, and all experimental use must comply with applicable institutional and regulatory requirements.

1. Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s cytoprotection, Selye’s stress, and today. Current Pharmaceutical Design, 2018;24(18):2029-2039. Over 200 preclinical publications reviewing BPC-157’s effects on tendon healing, angiogenesis (VEGFR2), nitric oxide modulation, gastrointestinal protection, and musculoskeletal repair.

2. Xing Y, Ye Y, Zuo H, Li Y. Progress on the function and application of thymosin beta-4. Frontiers in Endocrinology, 2021;12:767785. Reviewed TB-500/thymosin beta-4 mechanisms, including actin polymerization, cell migration, angiogenesis, and tissue repair in preclinical models.

3. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates the healing of transected rat Achilles tendon and in vitro stimulates tendocyte growth. Journal of Orthopedic Research, 2003;21(6):976-983. Demonstrated BPC-157-accelerated Achilles tendon healing with improved breaking strength and collagen organization in a rat transection model.

4. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta-4 defined by active sites in short peptide sequences. FASEB Journal, 2010;24(7):2144-2151. Characterized TB-500/thymosin beta-4 active regions are responsible for cell migration, anti-inflammatory activity, and wound healing acceleration.

5. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Current Pharmaceutical Design, 2014;20(7):1121-1125. Reviewed BPC-157’s angiogenic properties, including VEGFR2 upregulation, NO system interaction, and vascular repair in multiple preclinical injury models.

6. US Food and Drug Administration. Bulk drug substances nominated for inclusion on the 503B Bulks List: Category 2 substances. September 2023. Both BPC-157 and TB-500/Thymosin Beta-4 were placed on the Category 2 list.

7. World Anti-Doping Agency. 2025 Prohibited List: International Standard. BPC-157 is prohibited under S0 (Non-Approved Substances). TB-500 is listed under S2.2 as “Thymosin-Beta4 and its derivatives, e.g., TB-500.”

8. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopedic Research, 2010;28(9):1155-1161. Demonstrated BPC-157-accelerated medial collateral ligament healing in rats with improved biomechanical properties.

9. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999;113(3):364-368. Early demonstration of thymosin beta-4/TB-500 wound healing acceleration through cell migration and angiogenesis.

10. Hsieh PS, Jin JS, Chiang CF, Tsai CL, Chang CH, Tsai TL. BPC 157 can effectively induce mesenchymal stem cells to differentiate along the tenogenic lineage. Journal of Tissue Engineering and Regenerative Medicine, 2017;11(5):1321-1330. Demonstrated BPC-157 induction of tenogenic differentiation in mesenchymal stem cells, supporting its role in tendon-specific repair.

BPC-157 TB-500 Blend is sold by Healius Peptides exclusively for in vitro research and laboratory use. It is not intended for human or veterinary therapeutic use, food, cosmetic, or household application. This product is not a drug, food supplement, or cosmetic product, and it may not be misbranded, misused, or mislabelled as such. By purchasing this product, the buyer acknowledges that it will be used solely for research purposes in accordance with all applicable local, state, national, and international laws and regulations. Healius Peptides assumes no liability for any misuse of this product.